|Bid||17.99 x 900|
|Ask||0.00 x 1100|
|Day's Range||21.83 - 22.71|
|52 Week Range||15.14 - 22.71|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.73|
Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its semi-automated ORTHO OPTIX™ Reader, which allows lower-volume transfusion labs to elevate their standard of patient care with the quality of results expected of an automated platform, is now available in the United States and Puerto Rico.
Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced the launch of the first quantitative COVID-19 IgG antibody test in addition to a total COVID-19 nucleocapsid antibody test.
RARITAN, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to present in two upcoming investor conferences: UBS Virtual Global Healthcare Conference on Monday, May 24, 2021 at 11:00am ETGoldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 1:30pm ET Interested parties can access a live webcast and replay of each presentation on the “Investors” portion of the Company’s website at https://ir.orthoclinicaldiagnostics.com/, under the “Events” section. Management will also be hosting individual meetings with investors at both of the conferences. About Ortho Clinical Diagnostics Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the world’s largest pure-play in vitro diagnostics (IVD) companies. More than 800,000 patients across the world are impacted by Ortho’s tests each day. Because Every Test is a Life™, Ortho provides hospitals, hospital networks, clinical laboratories and blood banks around the world with innovative technology and tools to ensure test results are fast, accurate, and reliable. Ortho's customized solutions enhance clinical outcomes, improve efficiency, overcome lab staffing challenges and reduce costs. From launching the first product to determine Rh+ or Rh- blood type, developing the world’s first tests for the detection of antibodies against HIV and hepatitis C, introducing patented dry-slide technology and marketing the first U.S. Food and Drug Administration-authorized high-volume antibody and antigen tests for COVID-19, Ortho has been a pioneering leader in the IVD space for over 80 years. The company is powered by Ortho Care™, an award-winning, holistic service and support program that ensures best-in-class technical, field and remote service and inventory support to laboratories in more than 130 countries and territories around the globe. For more information, visit Ortho’s website or social media channels: LinkedIn, Twitter, Facebook and YouTube. Investors: IR@orthoclinicaldiagnostics.com Media: firstname.lastname@example.org